DuckworthW.C.Insulin degradation: mechanism, products and significance.Endocr Rev1988; 9: 319–45.
2.
FullerJ.H., ShipleyM.J., RoseG.Coronary heart disease risk and impaired glucose tolerance: the white hall study.Lancet1983; 1: 1373–6.
3.
PyoralaK.Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland.Diabetes Care1979; 2: 131–41.
4.
ReavenG.M., LernerR.L., SternM.P.Role of insulin in endogenous hypertriglyceridemia.J Clin Invest1967; 46: 1756–67.
5.
ReavenG.M.Role of abnormalities of carbohydrate and lipoprotein metabolism in the pathogenesis and clinical cause of hypertension.J Cardiovasc Pharmacol1990; 15: 54–7.
6.
MicossiP., CristalloM., LibrentiC.Free-insulin profiles after intraperitoneal, intramuscular and subcutaneous insulin administration.Diabetes Care1986; 9: 575–8.
7.
AmairP., KhannaR., LeibelB.Continuous ambulatory peritoneal dialysis in diabetics with end-stage renal disease.N Engl J Med1982; 306: 625–30.
8.
ChenH.C., LaiY.H., TsaiC.Y.Continuous ambulatory peritoneal dialysis in diabetic patients with endstage renal disease: experience with intraperitoneal insulin therapy.Kao Hsiung I Hsueh Ko Hsueh Tsa Chih1991; 7: 56–61.
9.
SaudekC.D., SelamJ-L, PittH.A.A preliminary trial of the programmable implantable medication system for insulin delivery.N Engl J Med1989; 321: 574–9.
10.
WoodD.J., GoodchildK., GuillouP.Management of “brittle” diabetes with a preprogrammable implanted insulin pump delivering intraperitoneal insulin.Br Med J1990; 301: 1143–4.
11.
WideroeT-E, SmebyL.C., BergK.J.Intraperitoneal (1251) insulin absorption during intermittent and continuous peritoneal dialysis.Kidney Int1983; 23: 22–8.
12.
RuotoloG., MicossiP., GalimbertiG.Effects of intraperitoneal versus subcutaneous insulin administration on lipoprotein metabolism in type I diabetes.Metabolism1990; 39: 598–604.
FlessnerM.F., DedrickR.L.Role of the liver in small solute transport during peritoneal dialysis.J Am Soc Nephrol1994; 5: 116–20.
16.
DohertyJ.F., GoldenM.H.N., BrooksS.E.H.Peroxisomes and the fatty liver of malnutrition: an hypothesis.Am J Clin Nutr1991; 54: 674–7.
17.
AlpersD.H., SabesinS.M., WhiteH.M.Fatty liver: biochemical and clinical aspects. In: SchiffL., SchiffE.R. eds. Diseases of the liver.7th ed.Philadelphia: V. B. Lippincott Co., 1993: 825–55.
18.
FreimanJ.P., HelfertK.E., HamrellM.R., SteinD.S.Hepatomegaly with severe steatosis in HIV seropositive patients.AIDS1993; 7: 379–85.
19.
QuigleyE.M.M., MarshM.N., ShafferJ.L., MarkinR.S.Hepatobiliary complications of total parenteral nutrition.Gastroenterology1993; 104: 286–301.
20.
WishingradM., PaasoB., GarciaG.Fatty liver due to heterozygous hypobeta-lipoproteinemia.Am J Gastroenterol1994; 89: 1106–7.
21.
KralJ.G., SchaffnerF., PiersonR.N., WangJ.Body fat topography as an independent predictor of fatty liver.Metabolism1993; 42: 548–51.
22.
PowellE.E., SearleJ., MortimerR.Steatohepatitis associated with limb lipodystrophy.Gastroenterology1989; 97: 1022–4.
23.
WanlessI.R., BargmanJ.M., OreopoulosD.G., VasS.I.Subcapsular steatonecrosis in response to peritoneal insulin delivery: a clue to the pathogenesis of steatonecrosis in obesity.Mod Pathol1989; 2: 69–74.
24.
LewisG.F., UffelmanF.D., SzetoL.W., WellerB., SteinerG.Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans.J Clin Invest1995; 95: 158–66.
25.
KatzJ., McGarryJ.D.The glucose paradox. Is glucose a substrate for liver metabolism?J Clin Invest1984; 74: 1901–9.
26.
GroveA., VybergB., VybergM.Focalfatty change of the liver.Virchows Arch A Pathol Anat Histopathol1991; 419: 69–75.
27.
BurrowsC.J., JonesA.W.Hepatic subcapsular steatosis in a patient with insulin dependent diabetes receiving dialysis.J Clin Pathol1994; 47: 274–5.
